降钙素对2型糖尿病周围神经病变伴骨质疏松患者疼痛治疗作用的观察

Effect of calcitonin on osteoporotic patients with diabetic peripheral neuropathy

目的观察降钙素对T2DM周围神经痛(PDN)伴骨质疏松患者的疗效。方法选择T2DM+PDN伴骨质疏松症患者39例,随机分为试验(A,20例)组和对照(B,19例)组。A组予降钙素(益盖宁,20μ,2次/周),B组予骨质疏松症基础治疗药物(钙剂、维生素D)。分别于试验开始时(0周),试验后2、4、8、12周进行疼痛评分。疼痛评分选用划线记录法(VAS)和面部表情量表法(FS),同时将患者对疗效的主观感觉分为无效、有效、显效。结果客观分析法提示两组间疗效差异有统计学意义(P_(VAS)=0.014,P_(FS)=0.014)。患者主观感觉第2周时差异无统计学意义(P=0.076),但第4、8、12周时差异有统计学意义。结论降钙素对T2DM+PDN伴骨质疏松患者具有改善作用,且呈时间依赖性,4周以上疗效显著。

Objective To investigate the effect of calcitonin on osteoporotic patients with painful diabetic neuropathy（PDN）. Methods Thirty-nine osteroprosis patients with T2DM and painful diabetic peripheral neuropathy were recruited for this study. They were randomized into the A group（n=20）, and the B group（n=19）. The A group was administered by calcitonin, 20 μ, twice a week, and the B group was given the basic treatment for osteoporosis （calcium, vitamin D）. Pain was assessed at 0, 2, 4, 8, 12 weeks of treatment using the Visual Analogue Scale （VAS） and the Wong-Baker Face Scale （FS）. At the same time, the patients＇ subjective assessments were recorded as ineffective, effective, and remarkable effective. Results Both VAS and FS scores showed that the difference in effects between the experiment and B groups was statistically significant （PvAs=0.014, PFS = 0.014）.The patients＇ subjective assessments at the 2nd week were not significantly different （P=0. 076）, while that at the 4th, 8th, and 12th weeks was significantly different. Conclusion Calcitonin is effective in improving the symptoms of osteoporotic patients with T2DM＋PDN in a time-dependant manner, and it is remarkably effective in the treatment over 4 weeks.